icone plus
Contact Abonnez-vous aux actualités
Reason for request
Inclusion
Clinical Benefit
Substantial
Substantial actual benefit
Clinical Added Value
important
KALYDECO offers a substantial improvement in actual benefit (IAB II) in the treatment of cystic fibrosis in patients aged 6 years and older with the G551D-CFTR mutation.
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
5C0srJc7hcj3JM8Y
Listen
